Employee Warrant Program Oversubscribed

C-RAD has launched a warrant program for its employees. The interest expressed exceeded the initial available volume by 42%.

The Extra Shareholder Meeting decided in March 2015 to issue 400,000 warrants for the purpose of using them as part of an employee incentive program for C-RAD AB. 200,000 warrants were initially offered to employees and 200,000 were issued to C-RAD Positioning AB, with permission for these to be transferred on one or more occasions to current or future employees.

Current employees of the entire C-RAD group signed up for a total of 284,330 options (of which members of the management team of C-RAD AB and C-RAD Positioning have signed up for 150,000 warrants), which is 42% more than the initial volume offered to the employees. It has therefore decided to offer the excess amount from the reserve created in C-RAD Positioning. A total number of 115,670 warrants will remain available for transfer to future employees.

Warrant agreements have been entered into with the employees, but the delivery of options under this program is contingent on the positive resolution of the Annual General Meeting (point 14 of the agenda) to offer available warrants throughout the entire C-RAD group.

“This result speaks very positively for the company and its team,” says Tim Thurn, CEO of C-RAD. “The commitment as well as the expectations that the management team and employees have regarding the development of the company can be visualized by the interest they have shown in the warrant program. This is an excellent mechanism for aligning the interests of our employees with those of our shareholders.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 31. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD Sentinel^TM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD holds 29% of the shares in laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).